A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Phase 1
Terminated
- Conditions
- Peritoneal CancerSolid TumorPeritoneal Metastases
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Enlivex Therapeutics RDO Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05581719
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sourasky Medical Center, Tel Aviv, Israel
🇪🇸ClÃnica Universidad de Navarra, Madrid, Spain
Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Enlivex Therapeutics RDO Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT05431907
- Locations
- 🇮🇱
The Chaim Sheba Medical Center, Ramat Gan, Israel
© Copyright 2025. All Rights Reserved by MedPath